Health & Fitness
Sat, September 3, 2011Fri, September 2, 2011Thu, September 1, 2011Wed, August 31, 2011Tue, August 30, 2011Mon, August 29, 2011Fri, August 26, 2011Thu, August 25, 2011Wed, August 24, 2011Tue, August 23, 2011Mon, August 22, 2011Sat, August 20, 2011Fri, August 19, 2011Thu, August 18, 2011Wed, August 17, 2011Tue, August 16, 2011Mon, August 15, 2011Fri, August 12, 2011Thu, August 11, 2011Wed, August 10, 2011Tue, August 9, 2011Mon, August 8, 2011Sun, August 7, 2011Sat, August 6, 2011Fri, August 5, 2011Thu, August 4, 2011Wed, August 3, 2011Tue, August 2, 2011Mon, August 1, 2011Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol
//health-fitness.news-articles.net/content/2011/ .. -grunenthal-for-the-development-of-axomadol.html
Published in Health and Fitness on Wednesday, August 17th 2011 at 23:41 GMT by Market WireEndo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development... -- CHADDS FORD, Pa., Aug. 17, 2011 /PRNewswire/ --
Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol
CHADDS FORD, Pa., Aug. 17, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: [ ENDP ]) announced today that it is terminating its research program and collaboration related to the development of axomadol. Endo licensed exclusive rights to develop and market axomadol in the United States and Canada from Grunenthal in February 2009.
"As a leader in the field of pain management, Endo remains committed to the development and commercialization of pain therapeutics," said Ivan Gergel, M.D., executive vice president, R&D, Endo Pharmaceuticals. "We have appreciated the opportunity to collaborate with Grunenthal on this program and they have been an excellent partner."
The company recently announced topline results from a phase 2 study comparing the novel investigational drug axomadol against placebo in the treatment of patients with moderate to severe chronic low back pain. The results indicate that axomadol did not meet predetermined study end points.
About Endo
Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments – branded pharmaceuticals, generics and devices and services. We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit [ http://www.endo.com/ ].
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
SOURCE Endo Pharmaceuticals
[ Back to top ] RELATED LINKS
[ http://www.endo.com ]
